Interpace Biosciences

Interpace Biosciences Debt

The Debt of Interpace Biosciences (IDXG) as of Nov 8, 2026 is 4.24 M USD. In the previous year, Debt was 11.17 M USD — a change of -62.00% (lower).

Debt

4.24 MUSD

YoY

-62.00%

Last updated:

In 2023, Interpace Biosciences's total debt was 4.24 M USD, a -62.00% change from the 11.17 M USD total debt recorded in the previous year.

The Interpace Biosciences Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2015
8.40 M USD
Jan 1, 2016
15.82 M USD
Jan 1, 2017
7.91 M USD
Jan 1, 2019
3.00 M USD
Jan 1, 2020
3.00 M USD
Jan 1, 2021
9.44 M USD
Jan 1, 2022
11.17 M USD
Jan 1, 2023
4.24 M USD
The Interpace Biosciences Debt history
YEARDebtYoY
4.24 MUSD-62.00%
11.17 MUSD+18.25%
9.44 MUSD+214.73%
3.00 MUSD0.00%
3.00 MUSD-62.06%
7.91 MUSD-50.00%
15.82 MUSD+88.35%
8.40 MUSD-84.54%
54.31 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Interpace Biosciences Stock analysis

What does Interpace Biosciences do? Interpace Biosciences develops and sells diagnostic clinical and pharma services, focusing on molecular tests for cancer risk evaluation. The company offers five commercialized tests: PancraGEN for pancreatic cancer diagnosis from cysts, PanDNA as a molecular snapshot of limited factors, ThyGeNEXT for thyroid cancer diagnosis using sequencing, ThyraMIR v2 used with ThyGeNEXT for thyroid cancer, and RespriDX to differentiate lung cancer origins. These products are sold to healthcare providers and laboratories seeking advanced diagnostic solutions for cancer risk assessment and treatment planning. Interpace Diagnostics, the company's division, provides bioinformatics and pathology services alongside its molecular tests. The tests target specific cancer types, with PancraGEN and PanDNA addressing pancreatic cancer, ThyGeNEXT and ThyraMIR v2 for thyroid cancer, and RespriDX for lung cancer differentiation. Healthcare institutions and physicians utilize these services to improve diagnostic accuracy and patient outcomes in oncology care. The company's revenue streams come from the direct sale of its molecular diagnostic tests and associated services to medical professionals and healthcare facilities. These services are positioned for precision medicine applications, supporting cancer diagnosis, prognosis, and treatment decisions. The business model relies on the clinical utility and technological innovation of its tests to drive adoption among healthcare providers focused on oncology diagnostics. Interpace Biosciences is one of the most popular companies on Eulerpool.

Debt Details

Understanding Interpace Biosciences's Debt Structure

Interpace Biosciences's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Interpace Biosciences's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Interpace Biosciences’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Interpace Biosciences’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Interpace Biosciences stock

Debt of Interpace Biosciences is 4.24 M USD in 2023.

Debt of Interpace Biosciences changed from 11.17 M USD to 4.24 M USD, representing a -62.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Interpace Biosciences since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Interpace Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Interpace Biosciences

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Interpace Biosciences